Engineers Gate Manager LP Xencor Inc Transaction History

Engineers Gate Manager LP

$5.42 Billion
Q4 2024

A detailed history of Engineers Gate Manager LP transactions in Xencor Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 8,792 shares of XNCR stock, worth $138,386. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,792

Previous 46,671 81.16%

Holding current value

$138,386

Previous $938,000 78.46%

% of portfolio

0.0%

Previous 0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$19.43 - $26.84 $735,988 - $1.02 Million	-37,879 Reduced 81.16%	8,792 $202,000
Q3 2024 Nov 14, 2024	SELL	$15.7 - $21.65 $471,015 - $649,521	-30,001 Reduced 39.13%	46,671 $938,000
Q2 2024 Aug 14, 2024	SELL	$18.21 - $24.5 $452,208 - $608,408	-24,833 Reduced 24.46%	76,672 $1.45 Million
Q1 2024 May 15, 2024	BUY	$18.65 - $26.52 $218,204 - $310,284	11,700 Added 13.03%	101,505 $2.25 Million
Q4 2023 Feb 14, 2024	BUY	$16.53 - $21.42 $1.3 Million - $1.69 Million	78,923 Added 725.26%	89,805 $1.91 Million
Q3 2023 Nov 14, 2023	BUY	$20.08 - $25.39 $41,987 - $53,090	2,091 Added 23.79%	10,882 $219,000
Q2 2023 Aug 14, 2023	BUY	$24.77 - $29.9 $217,753 - $262,850	8,791 New	8,791 $219,000
Q4 2022 Feb 14, 2023	BUY	$24.79 - $30.86 $252,560 - $314,401	10,188 New	10,188 $265,000
Q2 2022 Aug 15, 2022	BUY	$19.74 - $29.01 $243,394 - $357,693	12,330 New	12,330 $337,000
Q1 2022 May 16, 2022	SELL	$26.68 - $41.63 $318,132 - $496,396	-11,924 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$33.67 - $43.44 $401,481 - $517,978	11,924 New	11,924 $478,000
Q1 2020 May 15, 2020	SELL	$20.69 - $37.79 $315,688 - $576,599	-15,258 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$32.75 - $41.43 $499,699 - $632,138	15,258 New	15,258 $525,000

Others Institutions Holding XNCR

# of Institutions

199

Shares Held

73.7M

Call Options Held

1.7K

Put Options Held

4.2K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $940M
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.

Account

Engineers Gate Manager LP Xencor Inc Transaction History